[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335219-105":59,"doc-detail-335219-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-ribosome-biogenesis-as-a-novel-therapeutic-approach-to-overcome-emt-related-chemoresistance-in-breast-cancer","Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer","","Epithelial-to-mesenchymal transition (EMT) drives chemotherapy resistance and remains a major barrier in advanced breast cancer. This study uses a Tri-PyMT EMT lineage-tracing mouse model and single-cell RNA sequencing to map EMT and its reversal mesenchymal-to-epithelial transition (MET). Ribosome biogenesis (RiBi) increases during transition states, and RiBi-dependent nascent protein synthesis via ERK and mTOR is required for EMT/MET completion. Genetic or pharmacologic RiBi inhibition disrupts EMT/MET capability, and RiBi blockade combined with chemotherapy synergistically limits metastatic outgrowth.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-ribosome-biogenesis-as-a-novel-therapeutic-approach-to-overcome-emt-related-chemoresistance-in-breast-cancer/335219/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-ribosome-biogenesis-as-a-novel-therapeutic-approach-to-overcome-emt-related-chemoresistance-in-breast-cancer/335219.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in breast cancer treatment?","Question",{"text":112,"@type":113},"The study targets EMT-related chemoresistance in advanced breast cancer, where cells become more resistant to chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers study EMT and MET states?",{"text":117,"@type":113},"They used a Tri-PyMT EMT lineage-tracing model in mice and single-cell RNA sequencing to comprehensively analyze EMT status across transition phases, including MET.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does ribosome biogenesis (RiBi) play during EMT and MET?",{"text":121,"@type":113},"RiBi is elevated during EMT-to-MET transition phases, and RiBi-dependent nascent protein synthesis mediated by ERK and mTOR signaling is essential for completing EMT/MET.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335219,1790168264,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","RESEARCH ARTICLE  \n*For correspondence:  \n[yi.ban@nyulangone.org](yi.ban@nyulangone.org) (YB); [dig2009@med.cornell.edu](dig2009@med.cornell.edu) (DG)  \n†These authors contributed equally to this work  \nCompeting interest: The authors declare that no competing interests exist.  \nFunding: See page 17  \nSent for Review  \n05 June 2023  \nPreprint posted  \n29 June 2023  \nReviewed preprint posted  \n17 October 2023  \nReviewed preprint revised  \n20 August 2024  \nVersion of Record published  \n11 September 2024  \nReviewing Editor: Yongliang Yang, Dalian University of Technology, China  \n Copyright Ban, Zou et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use andredistribution provided that the original author and source are credited.  \nTargeting ribosome biogenesis as a novel therapeutic approach to overcome EMTrelated chemoresistance in breast cancer  \nYi Ban1,2*†, Yue Zou1,2†, Yingzhuo Liu1,2, Sharrel Lee1,2,3, Robert B Bednarczyk1,2, Jianting Sheng4, Yuliang Cao4, Stephen TC Wong4,5,6, Dingcheng Gao1,2,3,7*  \n1 Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, United States; 2Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, United States; 3 Neuberger Berman Lung Cancer Center, Weill Cornell Medicine, New York, United States; 4Systems Medicine and Bioengineering Department, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, United States; 5 Department of Radiology, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, United States; 6 Department of Pathology and Laboratory Medicine, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, United States; 7 Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, United States  \n\n| Abstract Epithelial-to-mesenchymal transition (EMT) contributes significantly to chemotherapy resistance and remains a critical challenge in treating advanced breast cancer. The complexity of EMT, involving redundant pro-EMT signaling pathways and its paradox reversal process, mesenchymal-to-epithelial transition (MET), has hindered the development of effective treatments. In this study, we utilized a Tri-PyMT EMT lineage-tracing model in mice and single-cell RNA sequencing (scRNA-seq) to comprehensively analyze the EMT status of tumor cells. Our findings revealed elevated ribosome biogenesis (RiBi) during the transitioning phases of both EMT and MET processes. RiBi and its subsequent nascent protein synthesis mediated by ERK and mTOR signalings are essential for EMT/MET completion. Importantly, inhibiting excessive RiBi genetically orpharmacologically impaired the EMT/MET capability of tumor cells. Combining RiBi inhibition with chemotherapy drugs synergistically reduced metastatic outgrowth of epithelial and mesenchymal tumor cells under chemotherapies. Our study suggests that targeting the RiBi pathway presents a promising strategy for treating patients with advanced breast cancer. |\n| --- |\n| eLife assessment\u003Cbr>This study presents a valuable finding that pathways associated with ribosome biogenesis (RiBi) are activated during transition cell states and targeting ribosome biogenesis could be a viable approach to overcome EMT-related chemoresistance in BCs. The evidence supporting the claims of the authors is quite solid, although inclusion of additional experimental support that blocking of EMT/MET is necessary for the synergistic effect of standard chemotherapy together with RiBi blockage would have strengthened the study. The work will be of interest to scientists working on breast cancer. |\n\nIntroduction  \nTumor cells exploit the transdifferentiation program of EMT to acquire aggressive properties, including anchorage-independent survival, invasion, and stemness (Nieto et al., 2016) . Multiple growth factors (TGFβ, EGF, Wnts, etc), signaling pathways (Smad2/3, PI3K/Akt, ERK1/2, etc), EMT transcription  \nBan, Zou et","cbCaieefGhBwOZtC","https://ap.wps.com/l/cbCaieefGhBwOZtC","pdf",2795976,"English","# Abstract\n# Introduction\n# eLife assessment\n# eLife digest","[{\"question\":\"What problem does the study address in breast cancer treatment?\",\"answer\":\"The study targets EMT-related chemoresistance in advanced breast cancer, where cells become more resistant to chemotherapy.\"},{\"question\":\"How did the researchers study EMT and MET states?\",\"answer\":\"They used a Tri-PyMT EMT lineage-tracing model in mice and single-cell RNA sequencing to comprehensively analyze EMT status across transition phases, including MET.\"},{\"question\":\"What role does ribosome biogenesis (RiBi) play during EMT and MET?\",\"answer\":\"RiBi is elevated during EMT-to-MET transition phases, and RiBi-dependent nascent protein synthesis mediated by ERK and mTOR signaling is essential for completing EMT/MET.\"}]","Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer | PDF",1790010203]